Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer.
MicroRNAs (miRNAs) have been reported to be involved in each stage of tumor development in various types of cancers. We have previously showed that miR-16 is downregulated in cancer and acts as a tumor suppressor. Other studies indicated that hepatocyte growth factor (HGF)/c-Met is implicated in proliferation, migration, and other pathophysiological processes. However, little is known about the relationship between miR-16 and HGF/c-Met in gastric cancer (GC). In the present study, we used bioinformatics tools and related experiments to search for miRNAs targeting HGF. Here, we found that miR-16 suppressed HGF protein expression by directly targeting 3'-untranslated region (UTR) of HGF mRNA. Subsequently, it was illustrated the downregulation of miR-16 promotes, while overexpressed of miR-16 significantly inhibits cell proliferation and migration by negatively regulating HGF/c-Met pathway. Moreover, the biological role of HGF in GC cells was determined by using HGF siRNA and HGF-overexpressing plasmid, respectively. To conclude, our results provide a potential target by using miR-16 for the future clinical treatment of GC.
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Shuang
http://orcid.org/0000-0002-9022-6112
S
Li
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Haiyang
H
Zhang
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Xinyi
X
Wang
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Yanjun
Y
Qu
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Jingjing
J
Duan
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Rui
R
Liu
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Ting
T
Deng
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Tao
T
Ning
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Le
L
Zhang
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Ming
M
Bai
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Likun
L
Zhou
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Xia
X
Wang
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China.
Shaohua
S
Ge
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China. yingguoguang163@163.com.
Guoguang
G
Ying
Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan Hu Xi Road 18, Tianjin, 300060, China. bayi@tjmuch.com.
Yi
Y
Ba
D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D016022:Case-Control Studies; D002465:Cell Movement; D049109:Cell Proliferation; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D014407:Tumor Cells, Cultured
D014408:Biomarkers, Tumor; C505362:MIRN16 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; D017228:Hepatocyte Growth Factor
GC; HGF; Migration; Proliferation; miR-16
Lancet. 2015 Mar 14;385(9972):977-1010
25467588
Oncotarget. 2016 Jun 21;7(25):38036-38051
27191259
PLoS One. 2015 May 26;10(5):e0126890
26010149
FEBS Lett. 2012 Mar 23;586(6):722-8
22321642
Ann Surg. 2005 Nov;242(5):676-83
16244541
Lancet. 2009 Aug 8;374(9688):477-90
19625077
APMIS. 2000 Mar;108(3):195-200
10752688
Oncotarget. 2014 Nov 30;5(22):11631-40
25373785
Cancer Res. 2004 Sep 1;64(17):6109-18
15342394
Oncology. 2002;63(3):286-96
12381909
Nature. 2004 Sep 16;431(7006):350-5
15372042
Annu Rev Pathol. 2014;9:287-314
24079833
Haematologica. 2011 Jul;96(7):1015-23
21486864
Mol Cell Biol. 2007 Mar;27(6):2240-52
17242205
Oncotarget. 2014 Jul 15;5(13):4855-67
24952592
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
12434020
Acta Otolaryngol. 2006 Jan;126(1):88-94
16308260
Cancer Res. 2009 Jul 1;69(13):5553-9
19549910
Nat Rev Cancer. 2006 Apr;6(4):259-69
16557279
Eur J Cancer. 2011 Mar;47(5):784-91
21112772
Adv Cancer Res. 2000;79:39-90
10818677
CA Cancer J Clin. 2015 Mar;65(2):87-108
25651787
Br J Haematol. 2008 May;141(5):672-5
18318758
Cell. 2004 Jan 23;116(2):281-97
14744438
Mol Med Rep. 2009 Nov-Dec;2(6):963-70
21475928
Korean J Intern Med. 2006 Mar;21(1):20-7
16646560
Clin Chem. 2012 Mar;58(3):610-8
22194634
Nat Rev Cancer. 2006 Nov;6(11):857-66
17060945
Int J Mol Sci. 2014 Aug 15;15(8):14298-312
25196524
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
16166262
Cell. 2009 Jan 23;136(2):215-33
19167326
Cell Death Dis. 2012 Nov 15;3:e423
23152059
Clin Res Hepatol Gastroenterol. 2016 Nov;40(5):538-545
27179559
Cell Death Differ. 2010 Feb;17(2):215-20
19498445
Oncol Rep. 1998 Sep-Oct;5(5):1013-24
9683803
Yale J Biol Med. 2006 Dec;79(3-4):131-40
17940623
BMC Cancer. 2010 Jul 12;10 :367
20618998
BMC Res Notes. 2014 Apr 29;7:271
24774510
Oncotarget. 2016 Jun 21;7(25):37812-37824
27192121
PLoS One. 2014 Apr 16;9(4):e95371
24740294
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1553-62
24817951